Saccharomyces boulardii: A possible addition to the standard treatment and prophylaxis of enterocolitis in Hirschsprung's disease?

Pediatric Surgery International

Volumn 18, Issue 5-6, 2002, Pages 567-

  Herek, O ^a  

^a PAMUKKALE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL TOXIN; METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN;

BACTERIAL INFECTION; BACTERIAL OVERGROWTH; CHILD; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; ENTEROCOLITIS; FECES ANALYSIS; HIRSCHSPRUNG DISEASE; HUMAN; INFECTION PREVENTION; LETTER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENT INFECTION; SACCHAROMYCES BOULARDII; TREATMENT INDICATION; SACCHAROMYCES;

ENTEROCOLITIS; HIRSCHSPRUNG DISEASE; HUMANS; PROBIOTICS; SACCHAROMYCES;

EID: 0036728534     PISSN: 01790358     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00383-002-0742-2     Document Type: Letter

References (8)

1. Teitelbaum DH, Coran AG, Weitzman JJ, Ziegler MM, Kane T (1998) Hirschsprung's disease and related neuromuscular disorders of the intestine. In: O'Neil JA, Rowe MI, Grosfeld JL, Fonkalsrud EW, Coran AG (eds) Pediatric surgey, 5th edn. Mosby Year Book, St Louis, pp 1381-1424
2. Wilson-Storey D, Scobie WG (1989) Impaired gastrointestinal mucosal defense in Hirschsprung's disease: a clue to pathogenesis of enterocolitis? J Pediatr Surg 24: 462-464
3. Thomas DF, Fernie DS, Malone M, Bayston R, Spitz L (1982) Association between Clostridium difficile and enterocolitis in Hirschsprung's disease. Lancet 1: 78-79
4. Buts JP, Bernasconi P, Vaerman JP, Dive C (1990) Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35: 251-256
5. Rodrigues ACP, Cara DC, Fretez SHGG, Cunha FQ, Vieira EC, Nicoli JR, Vieira LQ (2000) Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol 89: 404-414
6. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C (1999) Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67: 302-307
7. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, Harrington G, Rubin M, Greenwald D (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antiobiotics for Clostridium difficile disease. JAMA 271: 1913-1918
8. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, Elmer GW (2000) The search for a better treatment for reccurent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31: 1012-1017